Menu
Purified Membrane Proteins
CALIXAR’s Adenosine receptor A2A aids in the discovery, development, and validation of new molecules as well as therapeutic antibodies. This membrane protein is ideal for CNS neuroprotection in order to develop new treatments for insomnia, pain, depression, Alzheimer and Parkinson’s diseases.
Adenosine receptor A2A is a powerful therapeutic target especially found in the treatment of such conditions as insomnia, pain, depression, and Parkinson’s disease.
This class A GPCR is involved in the regulation of myocardial blood flow/hypertension. This protein has a N-terminal Step tag II and an 8X His tag followed by a TEV protease cleavage site.
Target name: Adenosine receptor A2A (A2AR)
Gene: ADORA2A
Uniprot Accession: P29274
Origin: Human (Homo sapiens)
Class: Class A GPCR
Sequence: Full-length, wild type sequence, with a N-terminus Strep tag II, 8xHis-tag, and TEV protease cleavage site.
Affinity Tag: His/Strep (both N-terminal)
Catalogue number: PP1
Theor. MW: 47,7kDa
Shipment temperature: Dry Ice
Storage conditions: Store at -80°C
Expression system: Sf9 insect cells (baculovirus)
Purity: >90%
Purification: Immobilized Metal Affinity Chromatography
Activity: Confirmed by radiobinding assay
Concentration: Up to 5mg/ml
Sample buffer: PBS, 0.05%/0.006% DDM/CHS OR
50mM Hepes pH 7.4, 200mM NaCl, 0.05%/0.006% DDM/CHS
Available quantity: From 10µg up to mg scale
€1,100.00 (10µg)
Ships in 7 business days
First in market
CALIXAR is the first to produce native, wild-type, unmutated and untruncated targets.
Better discovery
Develop reliable and effective drugs and antibodies as they are not locked in any specific conformation.
Why choose us?
CALIXAR’s Adenosine receptor A2A facilitates reliable fragment-based drug design (FBDD), structure-based drug discovery (SBDD) and antibody discovery corresponding to this specific target.
Unlike CALIXAR’s Adenosine receptor A2A, other alternative methods result in an adenosine receptor that becomes mutated and truncated (96 amino-acids truncation in the C-terminus). Additionally, this mutated version becomes locked within an antagonist conformation.
As with all GPCRs, the Adenosine receptor A2A is an unstable target and is difficult to produce natively with conventional approaches. Previously, Adenosine receptor A2A could only be locked in one specific conformation (e.g. antagonist) and were only ever prepared in a solution that inherently could not be pure, nor native (truncated, mutated) and without PTMs. A2AR’s have only ever been inherently unstable, but not anymore.
Today, CALIXAR’s Adenosine receptor A2A is able to bind to agonists, antagonists, as well as allosteric modulators (Igonet S. et al., 2018, Scientific Reports). Our Adenosine receptor A2A also maintain its structural and functional integrity and is purified and stabilized to full length and wild-type (native) proteins.
CALIXAR’s Adenosine receptor A2A is the first native full-length and functional target on the market. Other existing A2AR targets are either mutated or truncated. Our A2AR protein is produced in a eukaryotic system with the proper post-translational modifications (glycosylation).
CALIXAR’s Adenosine receptor A2A is high-quality membrane proteins used for (bio)drug discovery and are adapted for use in pharmaceutical, biotechnology companies, and as well as for academic teams that are involved in the life science fields.
Scientific Reports
Igonet S et al. 2018
Discovery on Target
Jawhari A. Boston, 2019
ANALYTICAL BIOCHEMISTRY
Desuzinges Mandon E. et al. 2017
Contact us
Starting from native material or recombinant systems, we succeed with all types of membrane proteins: GPCRs, Ions Channels, Transporters, Receptors and Viral Proteins.
© 2020 Calixar. All rights reserved.